Page last updated: 2024-12-05

chrysophanic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Chrysophanic acid is a natural anthraquinone pigment found in various plants, including rhubarb, buckthorn, and senna. It is known for its potential pharmacological properties, including anti-inflammatory, antioxidant, and anticancer activities. Research has shown that chrysophanic acid can inhibit the growth of cancer cells, including those of the breast, lung, and colon. Its anti-inflammatory effects are attributed to its ability to suppress the production of pro-inflammatory cytokines. Chrysophanic acid is also believed to have antioxidant properties due to its ability to scavenge free radicals. However, more research is needed to fully understand its mechanism of action and potential therapeutic applications. Further research is ongoing to explore its potential as a therapeutic agent in the treatment of various diseases, including cancer and inflammatory conditions. The study of chrysophanic acid is crucial as it holds promising therapeutic potential and can lead to the development of novel drugs for various diseases.'

chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
AloegenusA plant genus of the family Xanthorrhoeaceae which is used medicinally. It contains anthraquinone glycosides such as aloin-emodin or aloe-emodin (EMODIN).[MeSH]Asphodelaceae[no description available]
Aloe veraspeciesAloe vera (L.) Burm. f. and other species are used medicinally.[MeSH]Asphodelaceae[no description available]

Cross-References

ID SourceID
PubMed CID10208
CHEMBL ID41092
CHEBI ID3687
SCHEMBL ID308131
MeSH IDM0088412

Synonyms (113)

Synonym
BRD-K59284035-001-02-0
1,8-dihydroxy-3-methyl-anthraquinone
3-methyl-1,8-dihydroxyanthraquinone
4,5-dihydroxy-2-methylanthraquinone
turkey rhubarb
c.i. natural yellow 23
crysophanol
9, 1,8-dihydroxy-3-methyl-
2-methyl-4,5-dihydroxyanthraquinone
nsc-37132
nsc37132
c.i. 75400
anthraquinone,8-dihydroxy-3-methyl-
crysophanic acid
3-methylchrysazin
KBIO1_001361
DIVK1C_006417
SDCCGMLS-0066504.P001
1,8-dihydroxy-3-methylanthra-9,10-quinone
nsc-646567
SPECTRUM_000792
CHEBI:3687 ,
chrysophansaeure
1,8-dihydroxy-3-methyl-9,10-anthracenedione
1,8-dihydroxy-3-methyl-9,10-anthraquinone
BSPBIO_002825
SPECTRUM5_000153
nsc646567
1,8-dihydroxy-3-methyl-anthracene-9,10-dione
NCGC00091823-01
chrysophanic acid (1,8-dihydroxy-3-methylanthraquinone)
smr000156239
MLS000574888
nsc 37132
anthraquinone, 1,8-dihydroxy-3-methyl-
ccris 3525
nsc 646567
einecs 207-572-2
9,10-anthracenedione, 1,8-dihydroxy-3-methyl-
1,8-dihydroxy-3-methylanthraquinone
chrysophanic acid
chrysophanol
481-74-3
NCGC00091823-02
KBIO2_006408
KBIO3_002325
KBIO2_003840
KBIOGR_002053
KBIOSS_001272
KBIO2_001272
SPECPLUS_000321
SPECTRUM4_001477
SPBIO_000165
SPECTRUM2_000043
SPECTRUM3_001183
SPECTRUM300545
NCGC00091823-04
NCGC00091823-03
1,8-dihydroxy-3-methylanthraquinone, 98%
LMPK13040006
1,8-dihydroxy-3-methylanthracene-9,10-dione
C2505
dtxsid6024832 ,
NCGC00260048-01
tox21_202499
cas-481-74-3
dtxcid704832
n-(diaminomethylene)formamide;3-methylchrysazin
A827496
BCP9000004
CHRYSOPHANIC ACID - CHRYSOPHANOL
CCG-38348
unii-n1st8v8rr2
n1st8v8rr2 ,
hsdb 8483
FT-0623813
NCGC00091823-05
AKOS015905000
S2406
CHEMBL41092
chrysophanic acid [who-dd]
chrysophanic acid [mi]
SCHEMBL308131
bdbm50455992
Q-100527
1,8-dihydroxy-3-methylanthra-9,10-quinone #
mfcd00001208
HY-13595
SR-01000712223-2
sr-01000712223
AC-7980
chrysophanol, analytical standard
HMS3656G17
archinin
9,10-anthracenedione, 1,8-dihydroxy-3-methyl- (9ci)
1,8-dihydroxy-3-methyl-9,10-anthracenedione, 9ci
rumicin
4, 5-dihydroxy-2-methylanthraquinone
3-methyl-1, 8-dihydroxyanthraquinone
SW219732-1
DS-9706
8,9-dihydroxy-6-methyl-1,10-anthraquinone
chrysophanic acid (chrysophanol) ,
chrysophanic acid,(s)
BCP23439
Q15410875
BRD-K59284035-001-03-8
STL564344
EX-A6777
EN300-7401332
1,8-dihydroxy-3-methyl-9,10-dihydroanthracene-9,10-dione
rhenic acid
turkey-rhubarb

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Chrysophanic acid treatment in SNU-C5 cells inhibited EGF-induced phosphorylation of EGFR and suppressed activation of downstream signaling molecules, such as AKT, extracellular signal-regulated kinase (ERK) and the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (p70S6K)."( Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway.
Cha, EY; Kim, JY; Lee, MS; Song, IS; Sul, JY, 2011
)
2.53

Toxicity

ExcerptReferenceRelevance
" Adverse changes were associated with long-term AQ administration, and these focussed on the liver, lung and kidney, but after 15-day convalescence, most had reverted to normal."( Toxicity of anthraquinones: differential effects of rumex seed extracts on rat organ weights and biochemical and haematological parameters.
Abay, S; Abdugheny, A; Ali, Y; Islam, R; Ismayil, I; Kadir, M; Mamat, Y; Niyaz, M; Rapkat, H; Yan, M, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
"A validated high-performance liquid chromatography (HPLC) method was developed for simultaneous determination and pharmacokinetic study of aloe emodin and chrysophanol in rats."( Simultaneous determination and pharmacokinetic studies of aloe emodin and chrysophanol in rats after oral administration of Da-Cheng-Qi decoction by high-performance liquid chromatography.
Chen, GY; Huang, X; Liang, MZ; Qin, F; Tang, WF; Wan, MH; Wang, YG; Yu, Q, 2007
)
0.34
"SAP can significantly impact the absorption of DCQD components in rats and their pharmacokinetic parameters."( Effect of severe acute pancreatitis on pharmacokinetics of Da-Cheng-Qi Decoction components.
Chen, GY; Gong, HL; Huang, X; Liang, MZ; Tang, WF; Xia, Q; Xiang, J; Yu, Q, 2009
)
0.35
" The levels of aloe-emodin, rhein, emodin, chrysophanol, honokiol, magnolol, hesperidin, and naringin in rat serum were quantified using a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for pharmacokinetic study."( Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction [See Text] in rats.
Chen, GY; Gong, HL; Huang, X; Tang, WF; Wang, J, 2012
)
0.38
"The area under the curve (AUC), mean retention time (MRT), the peak concentration (C(max)) of aloe-emodin, rhein, emodin, and chrysophanol in the DCQD group were significantly different compared with the Dahuang group (P <0."( Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction [See Text] in rats.
Chen, GY; Gong, HL; Huang, X; Tang, WF; Wang, J, 2012
)
0.38
"The compatibility in Chinese medicine could affect the drug's pharmacokinetics in DCQD, which proves that the prescription compatibility principle of Chinese medicine formulations has its own pharmacokinetic basis."( Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction [See Text] in rats.
Chen, GY; Gong, HL; Huang, X; Tang, WF; Wang, J, 2012
)
0.38
" The validated method was successfully applied to the preclinical pharmacokinetic investigation of pogostone in rats after intravenous (5, 10 and 20 mg/kg) and oral administration (5, 10 and 20 mg/kg)."( LC-MS/MS determination of pogostone in rat plasma and its application in pharmacokinetic studies.
Chen, H; Chen, J; Lai, X; Li, C; Li, Q; Li, Y; Qin, Z; Su, Z; Wu, X; Yi, Y, 2013
)
0.39
" Comparing differences of pharmacokinetic properties of compounds in QYQRG between normal and blood stasis syndrome rabbits can provide much helpful information."( Comparative pharmacokinetics of rhein and chrysophanol after oral administration of Quyu Qingre granules in normal and acute blood stasis rabbits.
Dai, XY; Jiang, YQ; Liu, X; Wu, QF; Yan, YL; Yu, CH, 2014
)
0.4
" The concentrations of rhein and chrysophanol in rabbit plasma were determined by HPLC and main pharmacokinetic parameters were obtained."( Comparative pharmacokinetics of rhein and chrysophanol after oral administration of Quyu Qingre granules in normal and acute blood stasis rabbits.
Dai, XY; Jiang, YQ; Liu, X; Wu, QF; Yan, YL; Yu, CH, 2014
)
0.4
"The pharmacokinetic parameters AUC(0-∞), T(lag), Cmax and K21 of both rhein and chrysophanol were markedly different in the acute blood stasis model rabbits."( Comparative pharmacokinetics of rhein and chrysophanol after oral administration of Quyu Qingre granules in normal and acute blood stasis rabbits.
Dai, XY; Jiang, YQ; Liu, X; Wu, QF; Yan, YL; Yu, CH, 2014
)
0.4
" Based on the concentrations of rhein and chrysophanol in plasma determined by an established HPLC method, and the calculation of main total pharmacokinetic parameters, this study found that total pharmacokinetic parameters VRT, value of blood stasis group is lager than that of normal group and the difference is significant Compared with normal group, total pharmacokinetic parameters AUC,, MRT,, t1/2t, and Vt value of blood stasis group is lager, while the k, and CL, value is smaller."( [Total quantity statistical moment analysis on pharmacokinetics of rhein and chrysophanol after oral administration of Quyu Qingre granules in normal and acute blood stasis rabbits].
Dai, XY; Yan, YL, 2014
)
0.4
" Finally, we demonstrated the application of a validated method in a comparative pharmacokinetic study of rats receiving an oral dose of Dahuang Fuzi Decoction or Radix et Rhei Rhizoma, the monarch drug in the prescription."( Simultaneous quantification of chrysophanol and physcion in rat plasma by ultra fast liquid chromatography-tandem mass spectrometry and application of the technique to comparative pharmacokinetic studies of Radix et Rhei Rhizoma extract alone and Dahuang
Cai, BC; Cai, H; Li, H; Liu, X; Poh, Y; Wu, L; Xing, J, 2015
)
0.42
" This study was designed to confirm the expected synergistic effects of RGHP at pharmacodynamic and pharmacokinetic levels."( Synergistic effects of rhubarb-gardenia herb pair in cholestatic rats at pharmacodynamic and pharmacokinetic levels.
Dong, LC; Dong, X; Fan, YX; Li, HJ; Li, P; Ma, J; Yu, Q, 2015
)
0.42
" For pharmacodynamic study, biochemical and histopathological tests were performed to assess the hepatoprotective effects."( Synergistic effects of rhubarb-gardenia herb pair in cholestatic rats at pharmacodynamic and pharmacokinetic levels.
Dong, LC; Dong, X; Fan, YX; Li, HJ; Li, P; Ma, J; Yu, Q, 2015
)
0.42
" The pharmacokinetic study indicated RGHP could significantly elevate systemic exposure level and prolong retention time of five markers in comparison with rhubarb or gardenia alone."( Synergistic effects of rhubarb-gardenia herb pair in cholestatic rats at pharmacodynamic and pharmacokinetic levels.
Dong, LC; Dong, X; Fan, YX; Li, HJ; Li, P; Ma, J; Yu, Q, 2015
)
0.42
"The present study demonstrated the synergistic effects of RGHP in ANIT-induced cholestatic rats at pharmacodynamic and pharmacokinetic levels, and has significant enlightenments for the rational use of the related TCM formulas containing RGHP."( Synergistic effects of rhubarb-gardenia herb pair in cholestatic rats at pharmacodynamic and pharmacokinetic levels.
Dong, LC; Dong, X; Fan, YX; Li, HJ; Li, P; Ma, J; Yu, Q, 2015
)
0.42
" Pathological state is an important factor affecting the efficacy of drugs, the pharmacokinetic behavior of drugs could be significantly changed when people or animal were under different pathological state."( Nine components pharmacokinetic study of rat plasma after oral administration raw and prepared Semen Cassiae in normal and acute liver injury rats.
Cai, B; Jin, J; Peng, S; Qin, K; Sun, K; Xie, L; Yang, B; Zhen, Y, 2019
)
0.51
" (2) Methods: The three pharmacodynamic indicators are neurological function score, brain water content, and cerebral infarction area; UPLC-MS/MS was used in pharmacokinetic studies to detect plasma concentrations at different time points, and DAS software was used to calculate pharmacokinetic parameters in a noncompartmental model."( Pharmacodynamics of Five Anthraquinones (Aloe-emodin, Emodin, Rhein, Chysophanol, and Physcion) and Reciprocal Pharmacokinetic Interaction in Rats with Cerebral Ischemia.
Feng, SX; Li, JS; Li, RR; Liu, XF; Qu, LB; Shu, SN; Wang, PY; Zhang, N, 2019
)
0.51
" This review is intended to provide a comprehensive overview of the pharmacology, toxicity and pharmacokinetic researches of chrysophanol."( Chrysophanol: a review of its pharmacology, toxicity and pharmacokinetics.
Li, X; Long, J; Song, J; Tang, H; Xie, L; Zhang, L, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" Finally, the oral absolute bioavailability of pogostone in rats was calculated to be 70."( LC-MS/MS determination of pogostone in rat plasma and its application in pharmacokinetic studies.
Chen, H; Chen, J; Lai, X; Li, C; Li, Q; Li, Y; Qin, Z; Su, Z; Wu, X; Yi, Y, 2013
)
0.39
" Pharmacokinetic study in mice indicated that chrysophanol nanoparticle injection showed high bioavailability compared to the free chrysophanol."( Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo.
Li, K; Lu, L; Ma, B; Mao, YH; Qu, H; Wang, ZY; Yao, B; Zhong, WW, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The blood samples were collected before dosing and subsequently at 10, 15, 20, 30, 45 min, 1, 2, 4, 8, and 12 h following gavage."( Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction [See Text] in rats.
Chen, GY; Gong, HL; Huang, X; Tang, WF; Wang, J, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Bio Nutrition Total Colon Wellness -- 60 TabletsBio NutritionVitamins & SupplementsVitamin C, Turkey Rhubarb2024-11-29 10:47:42

Roles (3)

RoleDescription
antiviral agentA substance that destroys or inhibits replication of viruses.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dihydroxyanthraquinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
chrysophanol biosynthesis06
chrysophanol biosynthesis07

Protein Targets (53)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.62280.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency19.95260.004023.8416100.0000AID485290
Chain A, Breast cancer type 1 susceptibility proteinHomo sapiens (human)Potency39.81071.258920.440939.8107AID892
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency7.07950.125919.1169125.8920AID2549
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.90740.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency63.09570.031637.5844354.8130AID504865
GLI family zinc finger 3Homo sapiens (human)Potency23.75840.000714.592883.7951AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency2.73980.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency17.26920.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency12.58930.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency21.55050.001022.650876.6163AID1224838; AID1224839; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency25.11890.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency17.54350.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency6.54910.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency33.55960.005428.02631,258.9301AID1346982
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency16.96740.001019.414170.9645AID743191
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency79.43280.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency23.51740.000723.06741,258.9301AID743085; AID743122
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency26.96800.354828.065989.1251AID504847
histone deacetylase 9 isoform 3Homo sapiens (human)Potency14.46860.037617.082361.1927AID1259364; AID1259388
mitogen-activated protein kinase 1Homo sapiens (human)Potency3.16230.039816.784239.8107AID995
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency25.11890.65619.452025.1189AID927
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency16.69100.000627.21521,122.0200AID651741; AID743202; AID743219
DNA polymerase kappa isoform 1Homo sapiens (human)Potency18.85410.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Platelet-activating factor receptorHomo sapiens (human)Potency39.810710.000025.781039.8107AID892
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency6.68240.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency25.11891.584913.004325.1189AID927
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thioredoxin reductase 1, cytoplasmicRattus norvegicus (Norway rat)IC50 (µMol)194.00000.27201.82606.0000AID551520
TransthyretinHomo sapiens (human)IC50 (µMol)100.00000.16004.292110.0000AID1755162
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)46.21000.00032.177410.0000AID1141756
Neutrophil elastaseHomo sapiens (human)IC50 (µMol)18.00000.00632.073422.3780AID66482
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)36.12000.00101.453910.0000AID1141757
P2Y purinoceptor 12Homo sapiens (human)Ki10.00000.00202.82209.8300AID375433
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (125)

Processvia Protein(s)Taxonomy
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
positive regulation of cellular extravasationPlatelet-activating factor receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIPlatelet-activating factor receptorHomo sapiens (human)
chemotaxisPlatelet-activating factor receptorHomo sapiens (human)
inflammatory responsePlatelet-activating factor receptorHomo sapiens (human)
immune responsePlatelet-activating factor receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
parturitionPlatelet-activating factor receptorHomo sapiens (human)
response to symbiotic bacteriumPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of interleukin-6 productionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionPlatelet-activating factor receptorHomo sapiens (human)
inositol trisphosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of neutrophil degranulationPlatelet-activating factor receptorHomo sapiens (human)
transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of translationPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of blood pressurePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
cellular response to gravityPlatelet-activating factor receptorHomo sapiens (human)
cellular response to cAMPPlatelet-activating factor receptorHomo sapiens (human)
cellular response to fatty acidPlatelet-activating factor receptorHomo sapiens (human)
response to dexamethasonePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of leukocyte tethering or rollingPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of maternal process involved in parturitionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contractionPlatelet-activating factor receptorHomo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholinePlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
monoatomic ion transportP2Y purinoceptor 12Homo sapiens (human)
substrate-dependent cell migration, cell extensionP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
hemostasisP2Y purinoceptor 12Homo sapiens (human)
calcium-mediated signalingP2Y purinoceptor 12Homo sapiens (human)
cerebral cortex radial glia-guided migrationP2Y purinoceptor 12Homo sapiens (human)
cell projection organizationP2Y purinoceptor 12Homo sapiens (human)
lamellipodium assemblyP2Y purinoceptor 12Homo sapiens (human)
platelet activationP2Y purinoceptor 12Homo sapiens (human)
positive regulation of integrin activation by cell surface receptor linked signal transductionP2Y purinoceptor 12Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
positive regulation of monoatomic ion transportP2Y purinoceptor 12Homo sapiens (human)
response to axon injuryP2Y purinoceptor 12Homo sapiens (human)
regulation of chemotaxisP2Y purinoceptor 12Homo sapiens (human)
positive regulation of chemotaxisP2Y purinoceptor 12Homo sapiens (human)
establishment of localization in cellP2Y purinoceptor 12Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionP2Y purinoceptor 12Homo sapiens (human)
platelet aggregationP2Y purinoceptor 12Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 12Homo sapiens (human)
visual system developmentP2Y purinoceptor 12Homo sapiens (human)
positive regulation of ruffle assemblyP2Y purinoceptor 12Homo sapiens (human)
regulation of microglial cell migrationP2Y purinoceptor 12Homo sapiens (human)
positive regulation of microglial cell migrationP2Y purinoceptor 12Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
lipopolysaccharide bindingPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide immune receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor activityPlatelet-activating factor receptorHomo sapiens (human)
platelet activating factor receptor activityPlatelet-activating factor receptorHomo sapiens (human)
protein bindingPlatelet-activating factor receptorHomo sapiens (human)
phospholipid bindingPlatelet-activating factor receptorHomo sapiens (human)
mitogen-activated protein kinase bindingPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityPlatelet-activating factor receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
G protein-coupled adenosine receptor activityP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 12Homo sapiens (human)
guanyl-nucleotide exchange factor activityP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 12Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membranePlatelet-activating factor receptorHomo sapiens (human)
membranePlatelet-activating factor receptorHomo sapiens (human)
secretory granule membranePlatelet-activating factor receptorHomo sapiens (human)
tertiary granule membranePlatelet-activating factor receptorHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneP2Y purinoceptor 12Homo sapiens (human)
cell surfaceP2Y purinoceptor 12Homo sapiens (human)
membraneP2Y purinoceptor 12Homo sapiens (human)
cell projection membraneP2Y purinoceptor 12Homo sapiens (human)
cell body membraneP2Y purinoceptor 12Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (154)

Assay IDTitleYearJournalArticle
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID102411Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 3 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID360618Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID399963Cytotoxicity against HUVEC2004Journal of natural products, Mar, Volume: 67, Issue:3
Anthrone and oxanthrone C-glycosides from Picramnia latifolia collected in Peru.
AID1080765Antibacterial activity against Bacillus cereus using 50 uL of compound solution from 500 ug/mL stock solution after 24 hr by agar disk diffusion method2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID341236Antimicrobial activity against methicillin-resistant Pseudomonas aeruginosa DSM1117 on exposure to 2.5 W/cm'2 cold light for 40 secs at 1 to 100 uM2008Journal of natural products, Aug, Volume: 71, Issue:8
Uredinorubellins and caeruleoramularin, photodynamically active anthraquinone derivatives produced by two species of the genus ramularia.
AID399961Cytotoxicity against human LNCAP cells2004Journal of natural products, Mar, Volume: 67, Issue:3
Anthrone and oxanthrone C-glycosides from Picramnia latifolia collected in Peru.
AID755276Antidiabetic nephropathic activity in rat HBZY-1 cells assessed as inhibition of high concentration glucose-induced IL-6 production at 10 uM treated 1 hr before glucose challenge measured after 24 hrs by ELISA2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy.
AID327073Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 25 ug/ml2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID37282Inhibitory activity against rat alpha-glucosidase; mild activity observed2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Yeast and mammalian alpha-glucosidase inhibitory constituents from Himalayan rhubarb Rheum emodi Wall.ex Meisson.
AID1141754Inhibition of ovine COX1 using arachidonic acid as substrate at 30 uM preincubated for 10 mins before substrate addition measured after 5 mins by EIA2014European journal of medicinal chemistry, Jun-10, Volume: 80Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors.
AID360654Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1080760Antifungal activity against Rhizoctonia solani assessed as growth inhibition at 500 ug/mL after 2 days2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID1082590Antifungal activity against Blumeria graminis f. sp. hordei assessed as control of barley powdery mildew treated 1 day before inoculation2011Journal of agricultural and food chemistry, Nov-23, Volume: 59, Issue:22
Potent in vivo antifungal activity against powdery mildews of pregnane glycosides from the roots of Cynanchum wilfordii.
AID1091701Antifungal activity against Botryotinia fuckeliana assessed as growth inhibition at 0.01 to 200 ug/plug2009Letters in applied microbiology, Jun, Volume: 48, Issue:6
Factors affecting the production of Trichoderma harzianum secondary metabolites during the interaction with different plant pathogens.
AID1733309Antiproliferative activity against human NCI-H157 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Evaluation of the antiproliferative activity of 106 marine microbial metabolites against human lung cancer cells and potential antiproliferative mechanism of purpuride G.
AID1091700Antifungal activity against Leptosphaeria maculans isolate UWA P11 assessed as growth inhibition at 0.01 to 200 ug/plug2009Letters in applied microbiology, Jun, Volume: 48, Issue:6
Factors affecting the production of Trichoderma harzianum secondary metabolites during the interaction with different plant pathogens.
AID551521Inhibition of rat liver mitochondrial TrxR2 by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID98690In vitro inhibition of L1210 mouse leukemia cell proliferation.1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Novel type of potential anticancer agents derived from chrysophanol and emodin. Some structure-activity relationship studies.
AID19840Partition coefficient of compound in octanol and water by Fragmental method of Leo/Hansch2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Determination of active components in rhubarb and study of their hydrophobicity by micellar electrokinetic chromatography.
AID102410Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 10 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID1102425Antifungal activity against Sclerotinia sclerotiorum assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID327066Cytotoxicity against human M14 cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID755272Antidiabetic nephropathic activity in rat HBZY-1 cells assessed as inhibition of high concentration glucose-induced fibronectin production at 10 uM treated 1 hr before glucose challenge measured after 24 hrs by ELISA2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy.
AID1080758Antifungal activity against Botryotinia fuckeliana assessed as growth inhibition at 500 ug/mL after 4 days2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID360640Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID132501Inhibitory activity against nitric oxide production in LPS-activated mouse peritoneal macrophages2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Effects of stilbene constituents from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages.
AID1141757Inhibition of ovine COX2 using arachidonic acid as substrate preincubated for 10 mins before substrate addition measured after 5 mins by EIA2014European journal of medicinal chemistry, Jun-10, Volume: 80Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID260052Antiproliferative activity against prostate cancer PC3 cell line at 20 uM by MTT method2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID327068Cytotoxicity against human PC3 cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID335922Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of arachidonic acid-stimulated platelet aggregation pretreated 2 mins before arachidonic acid challenge
AID339134Inhibition of platelet activity factor-induced platelet aggregation in rabbit platelet-rich plasma at 50 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID289106Cytotoxicity against human KB cells2007Journal of natural products, Jun, Volume: 70, Issue:6
Alvaradoins E-N, antitumor and cytotoxic anthracenone C-glycosides from the leaves of Alvaradoa haitiensis.
AID341235Antimicrobial activity against methicillin-resistant Staphylococcus aureus DSM11729 on exposure to 2.5 W/cm'2 cold light for 40 secs at 1 to 100 uM2008Journal of natural products, Aug, Volume: 71, Issue:8
Uredinorubellins and caeruleoramularin, photodynamically active anthraquinone derivatives produced by two species of the genus ramularia.
AID356320Antioxidant activity assessed as DPPH radical scavenging activity2003Journal of natural products, Aug, Volume: 66, Issue:8
Sulfemodin 8-O-beta-D-glucoside, a new sulfated anthraquinone glycoside, and antioxidant phenolic compounds from Rheum emodi.
AID327069Cytotoxicity against human K562 cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID341228Reduction of cell viability in rabbit HIG82 cells at 2 uM followed by illumination at 2.5 W/cm'2 cold light for 40 seconds by XTT assay2008Journal of natural products, Aug, Volume: 71, Issue:8
Uredinorubellins and caeruleoramularin, photodynamically active anthraquinone derivatives produced by two species of the genus ramularia.
AID1062995Antiplasmodial activity against chloroquine-resistant ring stage Plasmodium falciparum Dd2 after 72 hrs by SYBR Green 1-based fluorescence assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Isolation of antiplasmodial anthraquinones from Kniphofia ensifolia, and synthesis and structure-activity relationships of related compounds.
AID1091702Antifungal activity against Phytophthora cinnamomi assessed as growth inhibition at 0.01 to 200 ug/plug2009Letters in applied microbiology, Jun, Volume: 48, Issue:6
Factors affecting the production of Trichoderma harzianum secondary metabolites during the interaction with different plant pathogens.
AID1083211Bactericidal activity against Erwinia amylovora 295/93 assessed as growth inhibition in King's B full medium measured at pH 7.2 after overnight incubation by suspension culture assay2012Journal of agricultural and food chemistry, Dec-12, Volume: 60, Issue:49
Potent and specific bactericidal effect of juglone (5-hydroxy-1,4-naphthoquinone) on the fire blight pathogen Erwinia amylovora.
AID1072523Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1102423Antifungal activity against Botryotinia fuckeliana assessed as inhibition of conidia germination at 1 to 10 ug/mL after 5 hr by light adverse phase microscopic analysis2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID363328Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID375433Displacement of [3H]PSB0413 from human platelet P2Y12 receptor2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.
AID399962Cytotoxicity against human MCF7 cells2004Journal of natural products, Mar, Volume: 67, Issue:3
Anthrone and oxanthrone C-glycosides from Picramnia latifolia collected in Peru.
AID285171Activity against planktonic Streptococcus mutans LMG 145582007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1072528Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID327064Cytotoxicity against human DU145 cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID327063Cytotoxicity against human ME180 cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID134177Compound (at 100 uM) was tested for inhibition against nitric oxide production in LPS-activated mouse peritoneal macrophages2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Effects of stilbene constituents from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages.
AID377974Antituberculosis activity against Mycobacterium tuberculosis at 12.5 ug/mL1999Journal of natural products, Jan, Volume: 62, Issue:1
Alvaradoins A-D. Anthracenone C arabinosides from alvaradoa jamaicensis
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID260051Antiproliferative activity against human epidermal carcinoma A431 cell line at 20 uM by MTT method2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID1315339Inhibition of human recombinant AKR1B10 expressed in Escherichia coli using DL-glyceraldehyde as substrate at 5 uM in presence of NADPH by spectrophotometric analysis2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID360647Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID260054Antifungal activity against Gibberella zeae at 0.5 mg/ml2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID341232Reduction of cell viability in mouse J774A.1 cells at 2 uM followed by illumination at 2.5 W/cm'2 cold light for 40 seconds by XTT assay2008Journal of natural products, Aug, Volume: 71, Issue:8
Uredinorubellins and caeruleoramularin, photodynamically active anthraquinone derivatives produced by two species of the genus ramularia.
AID66482Compound was tested for the enzyme inhibitory activity against Human Leukocyte Elastase (HLE) at 28 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID1102426Antifungal activity against Sclerotinia minor assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID67640Inhibitory activity against Porcine Pancreatic Elastase (PPE) at 28 uM concentration; NI = no inhibition1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID551520Inhibition of rat liver cytosolic TrxR1 by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID327065Cytotoxicity against human MCF7 cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID339133Inhibition of collagen-induced platelet aggregation in rabbit platelet-rich plasma at 50 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1877819Antiproliferative activity against human A-431 cells overexpressing EGFR assessed as reduction in cell survival at 10 uM2022Bioorganic & medicinal chemistry letters, 02-15, Volume: 58Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the U.S. National Cancer Institute database by in silico screening and bioactivity evaluation.
AID1072529Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1256630Inhibition of sEH (unknown origin) assessed as 6-methoxy-2-naphthaldehyde formation at 50 uM by fluorometry assay using 40 uM cyano-(6-methoxy-naphthalen-2-yl)-methyl ester as substrate2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Constituents of the seeds of Cassia tora with inhibitory activity on soluble expoxide hydrolease.
AID285172Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 5 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID755273Antidiabetic nephropathic activity in rat HBZY-1 cells assessed as inhibition of high concentration glucose-induced collagen-4 production at 10 uM treated 1 hr before glucose challenge measured after 24 hrs by ELISA2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy.
AID37426Inhibitory activity against yeast alpha-glucosidase; mild activity observed2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Yeast and mammalian alpha-glucosidase inhibitory constituents from Himalayan rhubarb Rheum emodi Wall.ex Meisson.
AID327067Cytotoxicity against human HT29 cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID357642Cytotoxicity against human KB cells2001Journal of natural products, Sep, Volume: 64, Issue:9
Cytotoxicity of Rhamnosylanthraquinones and Rhamnosylanthrones from Rhamnus nepalensis.
AID1102427Antifungal activity against Botryotinia fuckeliana assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID1733337Antiproliferative activity against human NCI-H157 cells assessed as cell viability at 50 uM measured after 72 hrs by sulforhodamine B assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Evaluation of the antiproliferative activity of 106 marine microbial metabolites against human lung cancer cells and potential antiproliferative mechanism of purpuride G.
AID327061Cytotoxicity against BALB/c mouse 3T3 cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID260049Inhibitory activity on PDGF-induced ERK phosphorylation in NIH3T3 cells at 20 uM2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID1594063Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark condition
AID360633Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1733310Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Evaluation of the antiproliferative activity of 106 marine microbial metabolites against human lung cancer cells and potential antiproliferative mechanism of purpuride G.
AID339132Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich plasma at 50 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID335924Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of collagen-stimulated platelet aggregation pretreated 2 mins before collagen challenge
AID1141758Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX22014European journal of medicinal chemistry, Jun-10, Volume: 80Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors.
AID399960Cytotoxicity against human Lu1 cells2004Journal of natural products, Mar, Volume: 67, Issue:3
Anthrone and oxanthrone C-glycosides from Picramnia latifolia collected in Peru.
AID48225Inhibitory activity against Cathepsin G (CatG) at 28 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID1315340Inhibition of human recombinant AKR1A1 expressed in Escherichia coli using DL-glyceraldehyde as substrate at 5 uM in presence of NADPH by spectrophotometric analysis2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID260053Antifungal activity against Fusarium oxysporum at 0.5 mg/ml2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID102409Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 1 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID1315337Inhibition of human recombinant aldose reductase expressed in Escherichia coli using DL-glyceraldehyde as substrate at 100 uM in presence of NADPH by spectrophotometric analysis2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID343962Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID1080766Antibacterial activity against Staphylococcus aureus using 50 uL of compound solution from 500 ug/mL stock solution after 24 hr by agar disk diffusion method2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID1141755Inhibition of ovine COX2 using arachidonic acid as substrate at 30 uM preincubated for 10 mins before substrate addition measured after 5 mins by EIA2014European journal of medicinal chemistry, Jun-10, Volume: 80Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors.
AID1755162Inhibition of acid-mediated aggregation of TTR V30M mutant (unknown origin) expressed in Escherichia coli pretreated for 30 mins at pH 7 followed by protein dilution in acetate buffer and further incubated for 96 hrs at pH 4.6 by thioflavin-T fluorescence2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID52613Inhibitory activity against Chymotrypsinogen at 28 uM concentration; NI = no inhibition1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID1594062Inhibition of baker's yeast alpha-glucosidase using PNPG as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins
AID260055Antifungal activity against Phytopthora infestans at 0.5 mg/ml2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID1733336Antiproliferative activity against human A549 cells assessed as cell viability at 50 uM measured after 72 hrs by sulforhodamine B assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Evaluation of the antiproliferative activity of 106 marine microbial metabolites against human lung cancer cells and potential antiproliferative mechanism of purpuride G.
AID339131Inhibition of ADP-induced platelet aggregation in rabbit platelet-rich plasma at 50 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID1102424Antifungal activity against Verticillium dahliae assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID363329Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID341234Antimicrobial activity against Staphylococcus aureus DSM1104 on exposure to 2.5 W/cm'2 cold light for 40 secs at 1 to 100 uM2008Journal of natural products, Aug, Volume: 71, Issue:8
Uredinorubellins and caeruleoramularin, photodynamically active anthraquinone derivatives produced by two species of the genus ramularia.
AID398699Inhibition of lipid peroxidation in Sprague-Dawley rat heart mitochondria assessed as inhibition of FeSO4-induced malondialdehyde formation up to 0.3 mM relative to control1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID327062Cytotoxicity against human H460 cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID338266Inhibition of Ca2+ ATPase activity in human red blood cells at 1600 uM by spectrophotometry1994Journal of natural products, Dec, Volume: 57, Issue:12
Novel Ca(2+)-ATPase inhibitors from the dried root tubers of Polygonum Multiflorum.
AID398698Inhibition of lipid peroxidation in Sprague-Dawley rat heart mitochondria assessed as inhibition of FeSO4-induced oxygen consumption up to 0.3 mM relative to control1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID67310Inhibitory activity against Human Leukocyte Elastase (HLE) at 28 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1080768Antibacterial activity against Pseudomonas aeruginosa using 50 uL of compound solution from 500 ug/mL stock solution after 24 hr by agar disk diffusion method2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID1141756Inhibition of ovine COX1 using arachidonic acid as substrate preincubated for 10 mins before substrate addition measured after 5 mins by EIA2014European journal of medicinal chemistry, Jun-10, Volume: 80Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors.
AID335923Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of ADP-stimulated platelet aggregation pretreated 2 mins before ADP challenge
AID1080767Antibacterial activity against Escherichia coli using 50 uL of compound solution from 500 ug/mL stock solution after 24 hr by agar disk diffusion method2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID360626Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID375434Displacement of [3H]PSB0413 from human platelet P2Y12 receptor at 10 uM2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.
AID755271Cytotoxicity against rat HBZY-1 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy.
AID327070Cytotoxicity against african green monkey Vero cells2008Journal of natural products, Jan, Volume: 71, Issue:1
Isolation of cytotoxic metabolites from targeted peruvian amazonian medicinal plants.
AID1062996Cytotoxicity against human A2780 cells2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Isolation of antiplasmodial anthraquinones from Kniphofia ensifolia, and synthesis and structure-activity relationships of related compounds.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (271)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (2.58)18.7374
1990's20 (7.38)18.2507
2000's75 (27.68)29.6817
2010's118 (43.54)24.3611
2020's51 (18.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.19 (24.57)
Research Supply Index5.63 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index68.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (1.81%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other272 (98.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]